HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gencell SA

Division of Sanofi

Latest From Gencell SA

Deals Shaping the Medical Industry (2/06)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

The Device Angle on Angiogenesis

Ten years ago, researchers observed that injecting vascular endothelial growth factors or fibroblast frowth factors into animal models of ischemia stimulated the formation of new blood vessels. The discovery that, with a bit of prompting, the body's natural capacity for angiogenesis could be accelerated, has drawn more than a dozen drug firms and a handful of cardiovascular device companies into the search for a biological alternative that can aid or replace current cardiovascular interventions, or even delay the progression of heart disease.
BioPharmaceutical Medical Device

Endocyte

Endocyte is using vitamins as targeting agents. It's beginning with folate as a cancer targeting agent, since many cancers have an abundance of folate receptors.
BioPharmaceutical

Can Genzyme Lower the Ante in Discovery?

Genzyme's added what it hopes will be a lower-cost discovery operation to its product-focused business. It's using tracking stock to keep the expenses off Genzyme Corp.'s P&L, and a pragmatic research approach that won't bet everything on a single technological direction. So far the market's not convinced.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • RPR Gencell
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Contact Info
  • Gencell SA
    Phone: (510) 784-1070
    3825 Bay Center Place
    Hayward, CA 94545-3619
    USA
UsernamePublicRestriction

Register